Prescribing Through Pregnancy: Trimester-by-Trimester Guidance on Azithromycin Safety and Maternal Counseling

For clinicians managing infections in pregnant patients, few decisions carry the same weight as antibiotic selection. The stakes are dual: inadequately treated infection poses measurable risk to both mother and fetus, while unnecessary or poorly chosen pharmacotherapy introduces its own set of concerns. Azithromycin occupies a complicated position in this calculus — widely used, generally familiar, and yet frequently mischaracterized by outdated classification systems that offer incomplete guidance for modern obstetric practice.

This article reviews the current teratogenicity evidence for azithromycin, organizes it by trimester-specific risk windows, compares it to relevant alternatives, and provides a practical counseling framework for clinical encounters.

Why FDA Category B No Longer Tells the Whole Story

Azithromycin was historically classified as FDA Pregnancy Category B, meaning animal studies demonstrated no fetal harm, and adequate human data were either absent or reassuring. When the FDA transitioned to its current narrative-based labeling system in 2015, that single-letter designation gave way to more granular language — but many clinicians still anchor their prescribing decisions to the old framework.

Category B was never a guarantee of safety. It was a signal that available data did not raise red flags, not that comprehensive human reproductive studies had been conducted. For azithromycin specifically, the bulk of safety data comes from observational cohort studies, retrospective analyses, and pharmacovigilance databases rather than controlled clinical trials — a distinction that matters when counseling patients who may interpret "Category B" as blanket reassurance.

First Trimester: Organogenesis and the Highest Stakes Window

The first trimester — particularly weeks three through ten — represents the period of active organogenesis, when fetal structures are most vulnerable to teratogenic disruption. This is where prescribing anxiety tends to peak, and where the evidence for azithromycin warrants the most careful reading.

Several large Scandinavian cohort studies, which benefit from robust national registry data, have examined macrolide exposure during the first trimester. A 2019 study published in the BMJ drew significant attention when it reported associations between first-trimester macrolide use and increased rates of certain cardiovascular and genital malformations. However, subsequent analyses — including replication attempts using US Medicaid data and the National Birth Defects Prevention Study — produced more mixed findings, with many failing to confirm the same associations after adjusting for confounders such as underlying infection severity and co-morbidities.

Erythromycin, notably, showed stronger and more consistent signals for cardiac malformations in some analyses than azithromycin did. This distinction is clinically relevant because erythromycin is sometimes reflexively chosen as a "safer" macrolide alternative in pregnancy — a practice that may not be well-supported by the comparative data.

For clinicians, the first-trimester guidance that emerges from this literature is not that azithromycin is definitively harmful, but that it should be prescribed for a clearly established indication rather than empirically or prophylactically. When a bacterial infection requires treatment and azithromycin is the most appropriate agent — for example, in confirmed Chlamydia trachomatis infection, where it remains a CDC-recommended option during pregnancy — the risk-benefit calculation generally supports its use.

Second Trimester: A Relatively Favorable Risk Window

By the second trimester, organogenesis is largely complete, and the risk profile for most antibiotic exposures shifts considerably. Fetal growth, neurological development, and organ maturation continue, but the acute vulnerability to structural malformation has passed.

The available evidence for azithromycin in the second trimester is generally reassuring. Studies examining mid-pregnancy macrolide exposure have not consistently identified elevated risks for adverse fetal outcomes when azithromycin is used at standard therapeutic doses. The drug's pharmacokinetic profile — characterized by extensive tissue distribution and a prolonged half-life — means that even short courses result in sustained tissue concentrations, a factor worth noting when timing exposure relative to gestational milestones.

In obstetric practice, second-trimester indications for azithromycin may include treatment of community-acquired pneumonia in patients with penicillin allergy, sexually transmitted infections, or atypical respiratory pathogens. In each scenario, clinicians should document the clinical indication clearly and confirm that the infection genuinely requires antibiotic intervention.

Third Trimester: Emerging Concerns About Neonatal Outcomes

The third trimester introduces a distinct set of considerations. Late-pregnancy antibiotic exposure may influence neonatal gut microbiome colonization, and some research has raised questions about associations between peripartum macrolide use and pyloric stenosis in neonates — a signal that has been observed more consistently with erythromycin than with azithromycin, but that clinicians should remain aware of.

A separate line of investigation has examined azithromycin's role in reducing preterm birth risk in women with lower genital tract infections, with some randomized data suggesting potential benefit. However, this use remains investigational and should not be extrapolated into routine prophylactic prescribing without further evidence.

For patients with preterm premature rupture of membranes (PPROM), azithromycin has been incorporated into some institutional protocols alongside ampicillin, based on data supporting reduced neonatal morbidity. Clinicians working in labor and delivery settings should be familiar with their institution's evidence-based protocols rather than defaulting to individual prescribing habits.

Comparing Azithromycin to Alternatives in Obstetric Settings

When azithromycin is being considered during pregnancy, a comparative analysis with available alternatives strengthens the prescribing rationale. Amoxicillin remains the preferred agent for many common bacterial infections in pregnancy and carries a well-established safety profile. For atypical organisms, however, beta-lactams offer no coverage, making macrolides or, in some cases, clindamycin the relevant alternatives.

Erythromycin, once the default macrolide in pregnancy, carries both tolerability limitations and the aforementioned teratogenicity signals that make azithromycin a reasonable comparator. Clarithromycin, by contrast, has shown more consistent adverse signals in animal studies and is generally avoided in pregnancy. Azithromycin therefore occupies a position as the macrolide with the most favorable contemporary safety data in obstetric patients — not risk-free, but comparatively well-characterized.

A Framework for Evidence-Based Patient Counseling

Patient anxiety around antibiotic use in pregnancy is common and understandable. Clinicians who dismiss these concerns or over-reassure patients risk eroding trust; those who amplify uncertainty without clinical context may contribute to non-adherence and undertreated infection. A structured counseling approach helps navigate this tension.

First, establish the clinical necessity. Explain why treatment is indicated and what the consequences of untreated infection may be — both for maternal health and fetal outcomes. Pregnant patients are often more receptive to treatment when they understand that the infection itself carries risk.

Second, contextualize the evidence honestly. Acknowledge that no antibiotic has been studied in randomized controlled trials in pregnant populations, explain what the observational data shows, and distinguish between statistical associations and confirmed causal harm.

Third, document the shared decision-making process. In medico-legal terms, a clearly documented conversation that reflects the patient's informed participation is protective for both clinician and patient.

Finally, provide follow-up parameters. Patients who know what to watch for — and who have a clear pathway to contact their provider — are better positioned to report adverse effects promptly.

Clinical Takeaway

Azithromycin is not contraindicated in pregnancy, but it is not without nuance. The evidence base, while imperfect, supports its use for established bacterial indications across all trimesters when the clinical rationale is sound and alternatives are less appropriate or unavailable. Clinicians who move beyond legacy category labels, engage with the primary literature, and apply individualized counseling frameworks will be best positioned to serve their pregnant patients — and to contribute to the responsible antibiotic stewardship that protects both current patients and future generations.